Sabin Nsanzimana

Dr. Sabin Nsanzimana


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Globalization and Health
Verified
Journal Article
Open access
PDF file
ABAgnes Binagwaho
Agnes Binagwaho
CNCameron T Nutt
Cameron T Nutt
VMVincent Mutabazi
Vincent Mutabazi
CKCorine Karema
Corine Karema
SNSabin Nsanzimana
Sabin Nsanzimana
PFPaul E Farmer
Paul E Farmer
The notion of “reverse innovation”--that some insights from low-income countries might offer transferable lessons for wealthier contexts--is increasingly common in the global health and business strategy literature. Yet the perspectives of researchers and policymakers in settings where these innovations are developed have been largely absent from the discussion to date. In this Commentary, we present examples of programmatic, technological, and research-based innovations from Rwanda, and offer reflections on how the global health community might leverage innovative partnerships for shared learning and improved health outcomes in all countries.

1 May 2015 in The Lancet HIV
Verified
Journal Article
Closed access
SNSabin Nsanzimana
Sabin Nsanzimana
SKSteve Kanters
Steve Kanters
EREric Remera
Eric Remera
JFJamie I Forrest
Jamie I Forrest
ABAgnes Binagwaho
Agnes Binagwaho
EMEdward J Mills
Edward J Mills

13 June 2016 in Tropical Medicine & International Health
Verified
Journal Article
Closed access
PDF file
JNJean D'AMour Ndahimana
Jean D'AMour Ndahimana
DRDavid J. Riedel
David J. Riedel
MMMutagoma Mwumvaneza
Mutagoma Mwumvaneza
DSDieudone Sebuhoro
Dieudone Sebuhoro
JUJean Claude Uwimbabazi
Jean Claude Uwimbabazi
SNSabin Nsanzimana
Sabin Nsanzimana

3 May 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
JMJean Damascene Makuza
Jean Damascene Makuza
JRJean Olivier Twahirwa Rwema
Jean Olivier Twahirwa Rwema
CNCorneille Killy NTIHABOSE
Corneille Killy NTIHABOSE
DDDonatha Dushimiyimana
Donatha Dushimiyimana
JUJustine Umutesi
Justine Umutesi
SNSabin Nsanzimana
Sabin Nsanzimana
The epidemiology of hepatitis B virus (HBV) infection in the general population in Rwanda is not well known. This study examined the prevalence of HBV surface antigen (HBsAg) positivity and associated risk factors among people aged 25 years and over in an organized national screening campaign. This is a cross-sectional study using data from a nationwide HBV screening campaign organized by the Rwanda Biomedical Centre from March to October 2018. This campaign targeted individuals aged > 25 years old from 24 of 30 districts of Rwanda. Sensitization was done through multimedia announcements, community health workers and local church leaders. During the campaign, a structured interview was administered by trained healthcare workers to collect information on socio-demographic, clinical and behavioral characteristics of participants; HBV screening was performed with HBsAg using enzyme-linked immunosorbent assays (ELISA) testing. Bivariate and multivariate logistic regressions were used to assess factors associated with HBsAg positivity in the screened participants. A total of 327,360 individuals were screened during the campaign. Overall 12,865(3.9%) were HBsAg positive. The highest prevalence (4.2%) was found in the 35–44-year-old group, but the difference from other groups was not significant (Odds Ratio [OR = 1.057, 95% Confidence Interval(CI) (0.904–1.235)]. Being male [OR = 1.348, 95% CI (1.30,1.40)]; being single [OR = 1.092, 95% CI (1.10–1.16)] compared to married; a previous positive TB screening test [OR = 2.352, 95% CI (1.63–3.39)]; history of surgical operation [OR = 1.082, 95% CI (1.00,1.17)]; exposure to traditional operational practices and scarification [OR = 1.187, 95% CI (1.13, 1.24)]; and having a person in the family with viral hepatitis [OR = 1.367, 95% CI (1.21, 1.53)] were significantly associated with HBV infection. These data provide the first national estimate of the prevalence of HBsAg seropositivity and its associated factors in Rwanda. The study identified people with the highest risk of HBV infection who should be the priority of future prevention efforts in Rwanda and in similar settings.

11 September 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MMMwumvaneza Mutagoma
Mwumvaneza Mutagoma
HBHelene Balisanga
Helene Balisanga
SMSamuel S. Malamba
Samuel S. Malamba
DSDieudonné Sebuhoro
Dieudonné Sebuhoro
EREric Remera
Eric Remera
SNSabin Nsanzimana
Sabin Nsanzimana
Hepatitis B virus (HBV) affects people worldwide but the local burden especially in pregnant women and their new born babies is unknown. In Rwanda HIV-infected individuals who are also infected with HBV are supposed to be initiated on ART immediately. HBV is easily transmitted from mother to child during delivery. We sought to estimate the prevalence of chronic HBV infection among pregnant women attending ante-natal clinic (ANC) in Rwanda and to determine factors associated with HBV and HIV co-infection. This study used a cross-sectional survey, targeting pregnant women in sentinel sites. Pregnant women were tested for hepatitis B surface antigen (HBsAg) and HIV infection. A series of tests were done to ensure high sensitivity. Multivariable logistic regression was used to identify independent predictors of HBV-HIV co-infection among those collected during ANC sentinel surveillance, these included: age, marital status, education level, occupation, residence, pregnancy and syphilis infection. The prevalence of HBsAg among 13,121 pregnant women was 3.7% (95% CI: 3.4–4.0%) and was similar among different socio-demographic characteristics that were assessed. The proportion of HIV-infection among HBsAg-positive pregnant women was 4.1% [95% CI: 2.5–6.3%]. The prevalence of HBV-HIV co-infection was higher among women aged 15-24 years compared to those women aged 25–49 years [aOR = 6.9 (95% CI: 1.8–27.0)]. Women residing in urban areas seemed having HBV-HIV co-infection compared with women residing in rural areas [aOR = 4.3 (95% CI: 1.2–16.4)]. Women with more than two pregnancies were potentially having the co-infection compared to those with two or less (aOR = 6.9 (95% CI: 1.7–27.8). Women with RPR-positive test were seemed associated with HBV-HIV co-infection (aOR = 24.9 (95% CI: 5.0–122.9). Chronic HBV infection is a public health problem among pregnant women in Rwanda. Understanding that HBV-HIV co-infection may be more prominent in younger women from urban residences will help inform and strengthen HBV prevention and treatment programmes among HIV-infected pregnant women, which is crucial to this population.

9 September 2015 in BMC Medicine
Verified
Journal Article
Open access
PDF file
SNSabin Nsanzimana
Sabin Nsanzimana
KPKrishna Prabhu
Krishna Prabhu
HMHaley McDermott
Haley McDermott
EKEtienne Karita
Etienne Karita
JFJamie I. Forrest
Jamie I. Forrest
ABAgnes Binagwaho
Agnes Binagwaho
The 1994 genocide against the Tutsi destroyed the health system in Rwanda. It is impressive that a small country like Rwanda has advanced its health system to the point of now offering near universal health insurance coverage. Through a series of strategic structural changes to its health system, catalyzed through international assistance, Rwanda has demonstrated a commitment towards improving patient and population health indicators. In particular, the rapid scale up of antiretroviral therapy (ART) has become a great success story for Rwanda. The country achieved universal coverage of ART at a CD4 cell count of 200 cells/mm3 in 2007 and increased the threshold for initiation of ART to ≤350 cells/mm3 in 2008. Further, 2013 guidelines raised the threshold for initiation to ≤500 cells/mm3 and suggest immediate therapy for key affected populations. In 2015, guidelines recommend offering immediate treatment to all patients. By reviewing the history of HIV and the scale-up of treatment delivery in Rwanda since the genocide, this paper highlights some of the key innovations of the Government of Rwanda and demonstrates the ways in which the national response to the HIV epidemic has catalyzed the implementation of interventions that have helped strengthen the overall health system.